Evidence map›Paper›PMID 37122719›Full record

ReviewFrontiers in immunology2023

Antigen-specificity measurements are the key to understanding T cell responses.

Rashmi Tippalagama, Leila Y Chihab, Kendall Kearns, Sloan Lewis, Sudhasini Panda, Lisa Willemsen, Julie G Burel, Cecilia S Lindestam Arlehamn

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Newly identified oncolytic VSV-GP-specific CD8Molecular therapy. Oncology · 2025
    Article
  16. Review
  17. UnveilingiScience · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Rashmi TippalagamaCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Leila Y ChihabCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Kendall KearnsCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Sloan LewisCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Sudhasini PandaCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Lisa WillemsenCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Julie G BurelCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
Cecilia S Lindestam ArlehamnCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States.
La Jolla Institute for Immunology · US

Funding

Single-cell atlas of lung tissue-resident memory T cells reactive to upper and lower respiratory tract pathogensU19AI118626 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Pandurangan Vijayanand · 2015 to 2026
$36.7M
Large Scale T Cell Epitope Discovery: Proteome-wide characterization of T cell epitopes from Mycobacterium tuberculosis in vaccination and active infection75N93019C00067 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI PETERS, BJOERN · 2019 to 2023
$4.5M
NIAID NIH HHS 75N93019C00067NIAID NIH HHS U19 AI118626
6 · The paper itself

Abstract

Antigen-specific T cells play a central role in the adaptive immune response and come in a wide range of phenotypes. T cell receptors (TCRs) mediate the antigen-specificities found in T cells. Importantly, high-throughput TCR sequencing provides a fingerprint which allows tracking of specific T cells and their clonal expansion in response to particular antigens. As a result, many studies have leveraged TCR sequencing in an attempt to elucidate the role of antigen-specific T cells in various contexts. Here, we discuss the published approaches to studying antigen-specific T cells and their specific TCR repertoire. Further, we discuss how these methods have been applied to study the TCR repertoire in various diseases in order to characterize the antigen-specific T cells involved in the immune control of disease.

Indexed as

Receptors, Antigen, T-CellT-LymphocytesAdaptive ImmunityAntibody SpecificityAntigensAntigensReceptors, Antigen, T-Celladaptive immunityantigen-specificitysequencingT cellTCR

Identifiers

PMID37122719
PMCPMC10140422
OpenAlexW4365515859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.